Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Analyst Ratings
Moderate Buy
11 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ABBV Stock 12 Month Forecast
Average Price Target
$213.93
▲(22.21% Upside)
| Highest Price Target$240.00 | Average Price Target$213.93 | Lowest Price Target$190.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
Reiterated
04/11/25
Wells Fargo
Reiterated
04/08/25
Goldman Sachs
Initiated
04/08/25
Morgan Stanley
Reiterated
04/07/25
Bernstein
Reiterated
04/02/25
Erste Group
Upgraded
03/17/25
Evercore ISI
Reiterated
03/17/25
Berenberg Bank
Reiterated
03/11/25
Leerink Partners
Reiterated
03/03/25
Bank of America Securities
Reiterated
03/03/25
BMO Capital
$215
Buy
22.82%
Upside
Reiterated
03/03/25
AbbVie's Strategic Expansion into Obesity Treatment with Gubra's Amylin Analogue: A Promising Investment
UBS
$181→$190
Hold
8.54%
Upside
Reiterated
02/03/25
Abbvie (ABBV) PT Raised to $190 at UBSUBS analyst Trung Huynh raised the price target on Abbvie (NYSE: ABBV) to $190.00 (from $181.00) while maintaining a Neutral rating.
Raymond James
$218→$220
Buy
25.68%
Upside
Reiterated
02/03/25
AbbVie price target raised to $220 from $218 at Raymond JamesAbbVie price target raised to $220 from $218 at Raymond James
Guggenheim
$212→$214
Buy
22.25%
Upside
Reiterated
02/02/25
AbbVie (ABBV) Receives a Buy from Guggenheim
Argus Research
$220
Buy
25.68%
Upside
Reiterated
01/31/25
AbbVie (ABBV) Receives a Buy from Argus Research
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
Reiterated
04/11/25
Wells Fargo
Reiterated
04/08/25
Goldman Sachs
Initiated
04/08/25
Morgan Stanley
Reiterated
04/07/25
Bernstein
Reiterated
04/02/25
Erste Group
Upgraded
03/17/25
Evercore ISI
Reiterated
03/17/25
Berenberg Bank
Reiterated
03/11/25
Leerink Partners
Reiterated
03/03/25
Bank of America Securities
Reiterated
03/03/25
BMO Capital
$215
Buy
22.82%
Upside
Reiterated
03/03/25
AbbVie's Strategic Expansion into Obesity Treatment with Gubra's Amylin Analogue: A Promising Investment
UBS
$181→$190
Hold
8.54%
Upside
Reiterated
02/03/25
Abbvie (ABBV) PT Raised to $190 at UBSUBS analyst Trung Huynh raised the price target on Abbvie (NYSE: ABBV) to $190.00 (from $181.00) while maintaining a Neutral rating.
Raymond James
$218→$220
Buy
25.68%
Upside
Reiterated
02/03/25
AbbVie price target raised to $220 from $218 at Raymond JamesAbbVie price target raised to $220 from $218 at Raymond James
Guggenheim
$212→$214
Buy
22.25%
Upside
Reiterated
02/02/25
AbbVie (ABBV) Receives a Buy from Guggenheim
Argus Research
$220
Buy
25.68%
Upside
Reiterated
01/31/25
AbbVie (ABBV) Receives a Buy from Argus Research
Best Analysts Covering AbbVie
Which Analyst Should I Follow If I Want to Buy ABBV and Sell After:
1 Month
xxx
Success Rate
16/25 ratings generated profit
Average Return
+3.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.00% of your transactions generating a profit, with an average return of +3.45% per trade.
3 Months
xxx
Success Rate
18/24 ratings generated profit
Average Return
+7.67%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.67% per trade.
1 Year
Success Rate
35/41 ratings generated profit
Average Return
+20.67%
assigned a buy rating 3 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 85.37% of your transactions generating a profit, with an average return of +20.67% per trade.
2 Years
xxx
Success Rate
24/25 ratings generated profit
Average Return
+30.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.00% of your transactions generating a profit, with an average return of +30.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ABBV Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
31
30
26
27
17
Hold
14
11
9
10
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
41
35
37
25
Each month's total comprises the sum of three months' worth of ratings.
ABBV Financial Forecast
ABBV Stock Forecast FAQ
What is ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is $213.93.
What is ABBV’s upside potential, based on the analysts’ average price target?
AbbVie has 22.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ABBV a Buy, Sell or Hold?
AbbVie has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.
What is AbbVie’s price target?
The average price target for AbbVie is $213.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $190.00. The average price target represents 22.21% Increase from the current price of $175.05.
The highest analyst price target is $240.00 ,the lowest forecast is $190.00. The average price target represents 22.21% Increase from the current price of $175.05.
What do analysts say about AbbVie?
AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of ABBV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.